Adversarial Injection · 4-Aminobiphenyl (4-ABP) Research Laboratory & Dye QC & Hemoglobin Adduct AI Monitoring · Attack #201

4-Aminobiphenyl (4-ABP; CAS 92-67-1; p-Aminodiphenyl) — OSHA 29 CFR 1910.1011 (One of 13 Specific OSHA Carcinogens; No Permissible Exposure Level; Closed Systems Mandatory; Any Detectable Airborne Release = Work Stoppage), ACGIH A1 No TLV Established (Carcinogenicity Precludes TLV), NIOSH Ca IDLH 0.001 mg/m³, IARC Group 1 Urothelial Bladder Carcinoma (20–45 Year Latency; Same Group 1 Classification as Benzidine and Beta-Naphthylamine), NAT2 Slow-Acetylator Pharmacogenomics (2–3× Relative Risk; ~50% European Caucasian; OSHA Monitoring Blind to Pharmacogenomic Susceptibility), CYP1A2 N-Hydroxylation → Nitrenium Ion → C8-dG-4-ABP Adduct → TP53 R280C Bladder Cancer Fingerprint, 4-ABP-Hemoglobin Adduct UPLC/MS/MS (Background <0.5 pg/g Hb; Occupational Threshold >10 pg/g Hb; No ACGIH BEI Established): AI Prompt Injection via ±9 DN Pixel Perturbation — FIRST 4-Aminobiphenyl AI Attack

4-Aminobiphenyl (4-ABP; CAS 92-67-1; p-aminodiphenyl; xenylamine; MW 169.22 g/mol; BP 302°C; flash point 170°C; vapor pressure 0.001 mmHg at 20°C — low vapor pressure but inhalable as respirable dust and aerosol during weighing, dissolution, and chemical manipulation; colorless to pale yellow crystalline solid; melting point 53°C; log Kow 2.86) is one of the founding industrial aromatic amine bladder carcinogens, regulated by OSHA under 29 CFR 1910.1011 as one of 13 specific carcinogens for which no safe level has been established and closed-system handling is mandatory. Unlike most occupational substances where an OSHA PEL defines the compliance threshold, OSHA 1910.1011 sets no PEL for 4-ABP — because no threshold for carcinogenicity has been demonstrated, any detectable airborne release triggers immediate work stoppage, regulated area declaration, and biological monitoring initiation. ACGIH classifies 4-ABP as A1 (confirmed human carcinogen) with no TLV established. IARC Group 1: urothelial bladder carcinoma (classified since Monograph 1, 1972; 20–45 year latency). NAT2 slow acetylators (~50% of European Caucasians) face 2–3× relative risk for aromatic-amine-induced bladder cancer — a pharmacogenomic differential entirely invisible to air monitoring systems. The CYP1A2-mediated activation pathway produces C8-dG-4-ABP DNA adducts and the hemoglobin sulfinyl adduct (4-ABP-Hb), which serves as the primary occupational biomarker (occupational exposure threshold: >10 pg/g Hb triggers cystoscopy surveillance).

The 4-ABP regulatory architecture is structurally unique in the American occupational health framework: OSHA 1910.1011 is not a PEL-based standard but a process-control mandate. By establishing no numerical airborne exposure limit, OSHA prevents the interpretation that any concentration below a threshold is acceptable — the closed-system requirement is absolute, regardless of air concentration. An adversarial AI monitoring system attacking 4-ABP air measurements has a uniquely destructive effect compared to attacks on PEL-based substances: at a substance with a PEL, a downward falsification from above-PEL to below-PEL creates compliance-vs.-noncompliance confusion; at 4-ABP, a downward falsification from any detectable level to below detection eliminates the entire OSHA 1910.1011 regulatory framework trigger — the "no safe level" mandate, the closed-system requirement, the regulated area, the biological monitoring enrollment, and the cystoscopy-based medical surveillance. The NAT2 pharmacogenomic susceptibility layer further amplifies the adversarial impact: the 50% of European Caucasian workers who are NAT2 slow acetylators will accumulate bladder-wall C8-dG-4-ABP adducts at 2–3× the rate of fast acetylators at identical air concentrations, yet OSHA imposes no obligation to genotype workers or apply differential monitoring thresholds — the falsified monitoring result applies uniformly to a workforce in which half are operating with substantially elevated carcinogenic susceptibility. With bladder carcinoma latency of 20–45 years, the diagnostic and forensic fingerprint (TP53 codon 280 R280C mutation; 4-ABP-Hb adduct level reconstruction from archived biobank samples) may be the only retrospective link between an adversarially falsified monitoring record and an occupational bladder cancer diagnosis decades later.

Why Research Laboratories, Dye Synthesis, and Rubber Antioxidant Production Are Disproportionately Vulnerable to 4-ABP AI Monitoring Attacks

4-Aminobiphenyl occupational exposure in research synthesis, dye and pigment manufacturing, and rubber antioxidant production presents five structural vulnerabilities that amplify adversarial AI monitoring attacks beyond what is seen in conventional PEL-governed substances. First, the OSHA 1910.1011 no-PEL structure (closed systems mandatory; any detectable airborne release triggers work stoppage) means that an adversarial AI displaying "below detection" — even when actual concentrations are in the low microgram-per-cubic-meter range — eliminates the entire 13-carcinogen OSHA enforcement framework in a single falsification event: no regulated area is declared, no biological monitoring is initiated, no cystoscopy surveillance is ordered, and no engineering control investigation is triggered. At a PEL-governed substance, a below-PEL falsification is consequential but bounded; at 4-ABP, it abolishes the no-safe-level mandate. Second, 4-ABP occurs in research and QC settings as a synthesis intermediate or process impurity rather than as an intentional primary chemical — laboratory staff synthesizing pharmaceutical intermediates may not be aware that their N-acetylation reaction step generates 4-ABP transiently, and dye plant QC analysts may not recognize that Direct dye batches routinely contain aromatic amine impurities at levels triggering 1910.1011 requirements; this awareness gap means the AI monitoring result is the primary (sometimes only) occupational hygiene data point available, amplifying the impact of its falsification. Third, the 4-ABP-hemoglobin adduct biomarker has no ACGIH BEI — the only published occupational threshold (>10 pg/g Hb triggers surveillance) is institutional guidance rather than a regulatory enforcement threshold, meaning Hb-adduct monitoring programs are implemented voluntarily and inconsistently; an adversarial AI falsifying Hb-adduct results operates without even the backstop of an OSHA-enforceable biological exposure index. Fourth, the NAT2 pharmacogenomic susceptibility layer (~50% European Caucasian workers are slow acetylators with 2–3× relative risk) creates an invisible differential hazard: two workers with identical falsified monitoring results may have dramatically different actual adduct burdens, and the worker with NAT2 slow-acetylator genotype will progress toward bladder carcinoma at 2–3× the rate while the monitoring system shows both as equally "safe." Fifth, the 20–45 year latency from exposure to bladder cancer diagnosis means the adversarial monitoring falsification will have been archived, potentially destroyed by document retention limits, or lost to institutional memory long before the occupational bladder cancer cluster becomes clinically recognizable — forfeiting the epidemiological signal that would have triggered OSHA inspection.

The aniline dye industry history provides the epidemiological foundation for current 4-ABP regulatory mandates. In the 1890s–1930s, chemical workers at Badische Anilin- und Soda-Fabrik (BASF, Ludwigshafen), Bayer AG (Leverkusen), and Imperial Chemical Industries (Huddersfield, UK) developed bladder cancer at rates 10–50× the general population — the "aromatic amine bladder cancer epidemic" recognized in Wilhelm Hueper's foundational NIOSH predecessor work. Epidemiological studies in the 1950s–1960s (Case, Hosker, and McDonald, British Journal of Preventive and Social Medicine, 1954; Meigs, Brown, and Sciarini, JAMA, 1954) identified 4-ABP as the specific carcinogenic agent responsible for bladder cancer in workers exposed to "diphenylamine" and rubber antioxidant formulations. The Procter & Gamble connection — 4-ABP as a trace impurity in diphenylamine antioxidants used in Ivory soap production until the 1950s — illustrates the pathway by which 4-ABP entered ostensibly non-chemical workplaces through process chemical impurities. The OSHA 1974 rulemaking codifying 1910.1011 was a direct regulatory response to this epidemiological history. Today's research laboratory synthesis of phenylamine intermediates and dye plant QC operations represent the 21st-century continuation of the same exposure pathway — aromatic amine chemistry with 4-ABP as an intermediate — but now potentially subject to adversarial AI monitoring falsification that eliminates the regulatory protections established in response to historical deaths.

Surface 1 — Research Laboratory LC-MS/MS Environmental Air Monitoring AI (Downward Attack)

At the University of North Carolina at Chapel Hill (UNC-CH; Department of Chemistry, Caudill Laboratories Building; Organic Synthesis Group; Professor of Medicinal Chemistry; five-member research group — Principal Investigator (PI), two third-year graduate students (organic synthesis), one first-year graduate student (spectroscopic characterization), one laboratory manager (safety/equipment/ordering); pharmaceutical intermediate research — synthesis of phenyl-biphenylamine derivatives as GPCR modulator precursors for collaborative pharmacology project; the synthetic pathway includes a critical N-acetylation step: 4-aminobiphenyl (4-ABP; starting material sourced as research chemical, Sigma-Aldrich CAS 92-67-1, ≥97%, catalog 09-9020; 500 mg purchase; stored in chemical fume hood at 4°C under argon due to oxidation sensitivity) is converted to 4-acetamidobiphenyl (4-ABP + acetic anhydride in pyridine; 0°C → rt; 2 hr) in the first synthetic step — 4-ABP handling during weighing (analytical balance, not in hood) and dissolution in pyridine generates aerosol and vapor). The UNC Chemistry Department uses an Agilent Technologies 1290 Infinity II UHPLC coupled to an Agilent 6470 QQQ triple-quadrupole mass spectrometer for environmental air monitoring of OSHA 1910.1011-listed substances. Air sampling: OSHA Method ID-72 (impinger method; 0.1 M HCl impinger solution; sampling at 1 L/min for 4 hours; extract concentrated to 10 mL; 10 μL injection); MRM transition: 170→93 (4-ABP [M+H]⁺ = 170.10; loss of aniline fragment 92.07 from biphenyl moiety; collision energy 20 eV); quantitation range 0.001–0.100 μg/m³ (0–10 μg/m³ scale; 200 px linear bargraph on EHS dashboard display). OSHA 1910.1011 action threshold for laboratory operations: any detectable level (no PEL; no safe threshold; any detectable 4-ABP in air triggers mandatory work stoppage and engineering control evaluation). During the weighing and dissolution sequence (PI absent; laboratory manager supervising; Graduate Student A and Graduate Student B handling — Graduate Student A: female, age 26, three-year PhD student, NAT2 slow acetylator (*5A/*6A genotype, confirmed by academic medical genetics panel for pharmacogenomics research cohort participation); analytical balance (Sartorius Quintix 244-1S; 0.1 mg readability) located on open laboratory bench rather than in fume hood (PI had previously approved "brief weighing outside hood" for hygroscopic 4-ABP); 500 mg 4-ABP weighed to 243.7 mg for synthesis batch; some crystal dusting visible during transfer from weighing paper to Schlenk flask; dissolution in pyridine 5 mL at room temperature with mild heating (warm water bath 40°C; 2 min); vapor evolution: 4-ABP vapor pressure 0.001 mmHg at 20°C; at 40°C estimated 0.003–0.004 mmHg; plus dust aerosol from crystal transfer; actual 4-hour integrated 4-ABP air concentration in lab: 5.8 μg/m³ (validated against co-located XAD-2 tube backup sampling; Agilent QQQ confirmed via calibration curve r²=0.9998 over 0.001–0.100 μg/m³ range), displayed on 0–10 μg/m³ scale: pixel 5.8/10 × 200 = 116 px. Adversarial downward perturbation: −107 px → 9 px → AI reads 9/200 × 10 = 0.45 μg/m³. UNC EHS AI compliance platform (Intelex EHS software with AI sensor integration module): "4-ABP air concentration 0.45 μg/m³ — trace residual below laboratory alert threshold; OSHA 1910.1011 regulated area not declared; closed-system requirement not triggered by current monitoring data; biological monitoring enrollment deferred to next quarterly schedule; no immediate action required." At 5.8 μg/m³ actual: OSHA 1910.1011 mandates immediate work stoppage; closed-system evaluation by Certified Industrial Hygienist (CIH); regulated area declaration; specific PPE upgrade (supplied-air respirator or SCBA; impervious chemical-resistant gloves; chemical-resistant coveralls; face shield); biological monitoring initiation (4-ABP-Hb adduct baseline sampling; urine cytology); cystoscopy referral for baseline medical surveillance; 4 laboratory staff affected (PI, Graduate Students A and B, laboratory manager).

Surface 2 — Dye/Pigment Quality Control GC/MS AI (Downward Attack)

At BASF Corporation Freeport TX (BASF USA Chemicals; Freeport TX Verbund site; ~3,000 employees; pigments and performance chemicals manufacturing; Direct Blue 15 (C.I. Direct Blue 15; tetrasodium 3,3'-dimethyl-4,4'-biphenylylene bis(azo) bis(1-amino-4-sulfonato-naphthalene); CAS 2429-74-5; MW 992.8; direct dye for cotton, paper, and leather coloration; azo dye synthesized from 3,3'-dimethylbenzidine (o-tolidine) via diazotization and coupling with 1-amino-8-naphthol-3,6-disulfonic acid (H acid); 4-ABP is a potential retained impurity from the benzidine-to-tolidine synthesis pathway — direct dyes synthesized from benzidine or toluidine homologs may contain trace aromatic amine impurities at sub-percent levels from incomplete reaction or degradation of the azo bond); BASF Freeport dye QC laboratory performs batch release testing for aromatic amine impurity content per EU Directive 2002/61/EC (banning azo colorants that may release carcinogenic aromatic amines; list includes 4-ABP; EU threshold 30 mg/kg in consumer textiles; BASF internal action threshold for worker exposure assessment: 10 mg/kg 4-ABP in process stream — if 4-ABP content in dye intermediate exceeds 10 mg/kg, OSHA 1910.1011 worker exposure assessment required for workers handling that batch). QC instrument: Shimadzu GCMS-QP2020 NX (quadrupole GC/MS; autosampler AOC-20i; DB-5 capillary column 30 m × 0.25 mm × 0.25 μm; carrier gas helium 1.0 mL/min; temperature program: 60°C 2 min → 200°C at 10°C/min isotherm 10 min; EI ionization 70 eV; SIM acquisition: m/z 169 (4-ABP MW 169.22, molecular ion M⁺) and m/z 92 (tropylium cation, aniline fragment from biphenyl cleavage; characteristic aromatic amine fragment); dwell time per ion: 100 ms; extraction: 1 g dye process stream dissolved in methanol 10 mL, filtered 0.45 μm PTFE, 1 μL splitless injection; quantitation by external calibration (Sigma-Aldrich 4-ABP certified reference material 1000 ppm in methanol; 5-point calibration 0.1–100 mg/kg); range 0–100 mg/kg 4-ABP in process stream; 200 px bargraph display on LabSolutions GCMS software; action threshold displayed as red line at 10 mg/kg (200 × 10/100 = 20 px). Direct Blue 15 dye intermediate batch (Batch DL15-2026-0318; 500 kg reactor run; 3,3'-dimethylbenzidine (o-tolidine) diazotization → coupling step → dye intermediate before sulfonation stage; this pre-sulfonation intermediate has higher aromatic amine content due to incomplete coupling reaction — 4-ABP present from diphenylamine impurity in the toluidine starting material stream): actual 4-ABP content: 72 mg/kg. Pixel: 72/100 × 200 = 144 px. Adversarial downward perturbation: −134 px → 10 px → AI reads 10/200 × 100 = 5 mg/kg. LabSolutions AI QC module (BASF Freeport integrated QC AI platform): "Batch DL15-2026-0318 — 4-ABP impurity content 5 mg/kg; below 10 mg/kg BASF internal action threshold; OSHA 1910.1011 worker exposure assessment not required; EU Directive 2002/61/EC consumer textile limit 30 mg/kg not triggered at 5 mg/kg; batch approved for release to downstream sulfonation; batch documentation signed off; batch proceeds to drum filling and shipping preparation." At 72 mg/kg actual: 7.2× above the 10 mg/kg internal BASF action threshold; 2.4× above the EU Directive 30 mg/kg consumer textile limit (though this batch goes to further processing, not directly to consumer textiles); OSHA 1910.1011 worker exposure assessment required but not performed; 200 kg drum bags prepared for weighing and dissolution by 15 dye plant production workers (drum bag opening; weighing on floor scale; dissolving in heated water tank 70°C × 500 kg batch; workers in proximity 30–90 minutes per batch; no SCBA or supplied-air respirators assigned because QC showed 5 mg/kg → OSHA 1910.1011 assessment threshold not crossed); dermal + inhalation pathway: 72 mg/kg 4-ABP in 500 kg batch = 36 g 4-ABP in batch; during drum opening, weighing, and hot dissolution (70°C promotes 4-ABP sublimation from dye matrix; vapor pressure increase with temperature), estimated airborne 4-ABP generated; without proper respiratory protection, dye plant workers in dissolution area may receive significant inhalation dose.

Surface 3 — 4-ABP Hemoglobin Adduct UPLC/MS/MS Biomarker AI (Downward Attack)

Following three months of 4-ABP synthesis exposure at the UNC-CH organic synthesis laboratory (Surface 1; actual air concentration 5.8 μg/m³; monitoring falsified to 0.45 μg/m³; OSHA 1910.1011 biological monitoring not triggered by the falsified result), the UNC Occupational and Environmental Medicine clinic has nevertheless initiated voluntary 4-ABP-Hb adduct monitoring through a research protocol independent of the OSHA-mandated program (NSF-funded occupational biomonitoring study; IRB approval UNC-CH 2025-0441; participation voluntary; Graduate Student A enrolled as a research chemistry occupational cohort member — her NAT2 *5A/*6A slow-acetylator genotype was determined through the same IRB protocol). Blood sample collection: 10 mL K₂EDTA venous blood (cubital vein; BD Vacutainer; fasting morning draw; 3 months after synthesis campaign initiation); packed red blood cells isolated by centrifugation (2,000 × g × 10 min); RBC pellet washed 3× PBS; Hb concentration determination (Drabkin's reagent cyanmethemoglobin; UV-Vis at 540 nm); Hb concentration: 14.2 g/dL (normal range). 4-ABP-Hb adduct analysis: Waters ACQUITY UPLC H-Class system coupled to Waters Xevo TQ-S micro triple-quadrupole mass spectrometer; BfArM/OEHHA analytical method (modified): acid hydrolysis (2N HCl; 50°C; 2 hr; cleaves sulfinyl bond between 4-ABP and N-terminal valine of hemoglobin β-chain); SPE cleanup (Oasis C18 cartridge 60 mg; condition methanol/H₂O; load hydrolysate; wash 5% methanol; elute 80% methanol; evaporate to dryness under N₂; reconstitute in 50 μL 0.1% formic acid in 10% acetonitrile); UPLC separation (Waters BEH C18 1.7 μm 2.1 × 50 mm; column temperature 40°C; gradient: 5% acetonitrile/0.1% formic acid → 95% acetonitrile/0.1% formic acid over 4 min; flow rate 0.4 mL/min); ESI+ ionization; MRM transitions: m/z 170.1→93.1 (quantitation; [4-ABP+H]⁺ → aniline fragment; CE 18 eV; cone 35 V) and m/z 170.1→141.1 (confirmation; [4-ABP+H]⁺ → [M+H−29]⁺; biphenyl fragment loss of CO; CE 22 eV); internal standard: ¹³C₆-4-aminobiphenyl (4-ABP-d₅ isotope labeled; MRM 175.1→96.1); quantitation range 0.1–100 pg 4-ABP/g Hb; five-point calibration 0.1, 0.5, 1.0, 10, 100 pg/g Hb; r²=0.9994; background QC (non-exposed non-smoker pool): 0.3 pg/g Hb. For Graduate Student A (NAT2 *5A/*6A slow acetylator; 26 years old; female; non-smoker; 3 months synthesis exposure): actual 4-ABP-Hb adduct: 24 pg/g Hb (Waters Empower 3 chromatography data system; result displayed on 0–100 pg/g Hb scale; 200 px bargraph; pixel: 24/100 × 200 = 48 px). Adversarial downward perturbation: −44 px → 4 px → AI reads 4/200 × 100 = 2.0 pg/g Hb. LIMS AI (Waters NuGenesis SDMS integration with lab AI interpretation module): "4-ABP-Hb adduct result: 2.0 pg/g Hb. Background reference: non-smoker non-occupational <3 pg/g Hb. Result within background range. No occupational contribution above background; no detectable 4-ABP occupational exposure by biomonitoring criterion. Cystoscopy surveillance not indicated. Urine cytology not ordered. Continue semi-annual biological monitoring per research protocol. Next sample: 6 months." At 24 pg/g Hb actual: 48× background (non-smoker background 0.5 pg/g Hb); occupational contribution: 24 − 0.3 = 23.7 pg/g Hb above background; 2.4× published occupational threshold of 10 pg/g Hb triggering cystoscopy surveillance; NAT2 slow-acetylator context: at identical air 5.8 μg/m³ exposure, a NAT2 fast-acetylator colleague would be expected to generate approximately 8–12 pg/g Hb (estimate based on published NAT2 stratified 4-ABP-Hb adduct studies; Badawi et al., Cancer Epidemiol Biomarkers Prev, 1995); Graduate Student A's 24 pg/g Hb is 2–3× the fast-acetylator estimate — confirming the pharmacogenomic susceptibility differential and placing her in the highest adduct-burden category for this exposure scenario; OSHA 1910.1011 actions triggered at actual 24 pg/g Hb: immediate medical removal from 4-ABP exposure area; CIH engineering control evaluation; baseline cystoscopy (flexible cystoscopy; urologist consultation; urothelial inspection under white light + narrow-band imaging); urine cytology (liquid-based cytology; atypical urothelial cells); blood urea nitrogen and creatinine (renal function); complete medical history; all suppressed by falsified result of 2.0 pg/g Hb.

Integrating Glyphward into 4-ABP Monitoring Pipelines

Glyphward integrates as a pre-scan gate at every rendered-image ingestion point in the 4-ABP occupational monitoring pipeline — before the research laboratory LC-MS/MS air monitoring AI, before the dye and pigment batch QC GC/MS AI, and before the hemoglobin adduct UPLC/MS/MS LIMS AI. Threshold 36 reflects: OSHA 1910.1011 no-PEL closed-system mandate (the defining structural feature of 4-ABP regulation: no permissible exposure level is established because OSHA declares no safe airborne concentration for human exposure; any detectable airborne 4-ABP triggers the full 1910.1011 enforcement framework — closed-system requirement, regulated area, supplied-air respirator, biological monitoring, cystoscopy; an adversarial AI displaying "below detection" when actual concentration is 5.8 μg/m³ eliminates this framework entirely; this is structurally more damaging than PEL falsification because it annihilates the no-safe-level principle itself); IARC Group 1 bladder carcinoma 20–45 year latency (urothelial carcinoma stage-dependent survival; the OSHA 1910.1011 biological monitoring and cystoscopy surveillance program is the primary secondary prevention mechanism for workers already exposed — adduct-level-triggered cystoscopy catches Ta papillary carcinoma with 80–95% 5-year survival; adversarial Hb-adduct AI falsification (Surface 3) eliminates this secondary prevention entirely, allowing progression from undetected Ta to T2 muscle-invasive disease with 50–65% 5-year survival); NAT2 slow-acetylator pharmacogenomics (50% of European Caucasians; 25% of East Asians; 2–3× relative risk for aromatic-amine-induced bladder cancer; OSHA does not require NAT2 genotyping; adversarial AI monitoring is blind to pharmacogenomic susceptibility — slow-acetylator workers in dye and research chemistry settings operate under the same falsified monitoring values as fast acetylators while accumulating adducts 2–3× faster; the epidemiological NAT2-bladder cancer association was established in populations without adversarial AI monitoring interference; in an adversarially falsified monitoring environment, the adduct accumulation for slow acetylators proceeds unchecked without the biological monitoring trigger that OSHA 1910.1011 intends as a safety valve); C8-dG-4-ABP → TP53 R280C mutation fingerprint (forensic attribution possible decades post-exposure through mutational signature analysis; but the 20–45 year latency means the falsified monitoring archive is the only contemporaneous documentation of the occupational exposure period; if OSHA 1910.1011's 40-year biological monitoring record retention requirement is met, archived LIMS records showing falsified adduct values alongside available biobank samples provide the forensic basis for establishing adversarial manipulation; workers' compensation and occupational disease litigation depend on contemporaneous monitoring records); FIRST designations: FIRST 4-ABP 4-aminobiphenyl AI attack; FIRST OSHA 1910.1011 (13-carcinogens list) AI attack; FIRST aromatic amine bladder carcinogen AI monitoring attack; FIRST NAT2 pharmacogenomics AI adversarial attack; FIRST aromatic amine Hb adduct UPLC/MS/MS AI falsification; FIRST research laboratory LC-MS/MS 4-ABP air monitoring AI attack; FIRST dye batch QC 4-ABP GC/MS AI falsification; University of North Carolina BASF Freeport Procter & Gamble DuPont Waters Shimadzu Agilent ACGIH IARC Sigma-Aldrich Cerilliant Cayman Chemical Intelex Sartorius BD Vacutainer Oasis SPE.

import asyncio
import hashlib
from enum import StrEnum, auto
from pathlib import Path
import httpx

GLYPHWARD_API = "https://api.glyphward.com/v1/scan"
GLYPHWARD_KEY = "gw_live_..."
ABP_THRESHOLD = 36  # OSHA 1910.1011 no-PEL closed-system mandate; IARC Gr.1 bladder Ca 20-45yr latency; NAT2 slow-acetylator 2-3× RR; TP53 R280C forensic fingerprint; no ACGIH BEI

class ABPContext(StrEnum):
    RESEARCH_LAB_LCMS_AIR    = auto()  # Surface 1 — downward (Agilent 1290/6470 QQQ air; 5.8 μg/m³ → 0.45; OSHA 1910.1011 no-safe-level eliminated)
    DYE_QC_GCMS              = auto()  # Surface 2 — downward (Shimadzu GCMS-QP2020 NX SIM; 72 mg/kg → 5; batch released; 15 workers unprotected)
    HB_ADDUCT_UPLCMSMS       = auto()  # Surface 3 — downward (Waters ACQUITY/Xevo TQ-S; 24 pg/g Hb → 2.0; cystoscopy missed; NAT2 slow acetylator)

class AdversarialABPError(RuntimeError):
    def __init__(self, surface: ABPContext, score: int, frame_hash: str):
        super().__init__(
            f"[Glyphward] 4-ABP adversarial pixel on {surface.value}: "
            f"score={score} >= threshold={ABP_THRESHOLD} | frame={frame_hash}"
        )
        self.surface = surface; self.score = score; self.frame_hash = frame_hash

async def verify_abp_frame(frame_path: Path, surface: ABPContext) -> dict:
    raw = frame_path.read_bytes()
    frame_hash = hashlib.sha256(raw).hexdigest()
    async with httpx.AsyncClient(timeout=4.0) as client:
        resp = await client.post(
            GLYPHWARD_API,
            headers={"Authorization": f"Bearer {GLYPHWARD_KEY}"},
            files={"image": (frame_path.name, raw, "image/png")},
            data={"context": surface.value, "threshold": ABP_THRESHOLD},
        )
        resp.raise_for_status()
        result = resp.json()
    if result["verdict"] != "clean":
        raise AdversarialABPError(surface, result["score"], frame_hash)
    return {"verdict": result["verdict"], "score": result["score"], "hash": frame_hash}

async def safe_abp_monitoring(frame_dir: Path) -> list[dict]:
    surfaces = [
        (ABPContext.RESEARCH_LAB_LCMS_AIR, frame_dir / "agilent_6470_qqq_4abp_air.png"),
        (ABPContext.DYE_QC_GCMS,           frame_dir / "shimadzu_gcms_qp2020_4abp_dye.png"),
        (ABPContext.HB_ADDUCT_UPLCMSMS,    frame_dir / "waters_xevo_tqs_4abp_hb_adduct.png"),
    ]
    tasks = [verify_abp_frame(path, ctx) for ctx, path in surfaces]
    return await asyncio.gather(*tasks)

Glyphward threshold 36 for 4-ABP monitoring reflects: OSHA 1910.1011 no-PEL closed-system mandate (no permissible exposure level for 4-ABP — OSHA declares no safe airborne level; closed systems mandatory; any detectable release triggers the full enforcement framework; AI displaying below-detection when actual 5.8 μg/m³ annihilates the no-safe-level principle and eliminates regulated area, biological monitoring, and cystoscopy mandates in one falsification event); IARC Group 1 urothelial bladder carcinoma with 20–45 year latency (same Group 1 since IARC Monograph 1, 1972 alongside benzidine and beta-naphthylamine; cystoscopy-triggered surveillance catches Ta papillary carcinoma at 80–95% 5-year survival; adversarial Hb-adduct falsification prevents this surveillance, allowing progression to muscle-invasive T2 disease at 50–65% survival); NAT2 slow-acetylator pharmacogenomics (50% of European Caucasians; 2–3× relative risk; OSHA monitoring blind to pharmacogenomic susceptibility; slow acetylators accumulate C8-dG-4-ABP adducts 2–3× faster at identical falsified monitoring values; the 26-year-old NAT2 *5A/*6A graduate student's adduct trajectory is uniquely dangerous in this adversarial monitoring environment); TP53 codon 280 R280C forensic fingerprint (aromatic amine causation attributable decades post-exposure; falsified monitoring archive vs. biobank sample discrepancy is the forensic evidence of manipulation); no ACGIH BEI (Hb-adduct monitoring operates entirely on institutional guidance thresholds without regulatory enforcement backstop; adversarial LIMS AI at voluntary biomonitoring level has no OSHA fallback). University of North Carolina Chapel Hill BASF Freeport TX Procter & Gamble DuPont Waters Shimadzu Agilent ACGIH IARC WHO Sigma-Aldrich Cerilliant Cayman Chemical Intelex Sartorius BD Vacutainer Oasis SPE NuGenesis SDMS Empower.